The Board of Directors of the Company at its meeting held today i.e. Monday, 12th May, 2025 at Registered Office of the Company has inter alia considered and approved the following businesses: ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.6 pts less than Nifty Microcap 250 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vivanza Biosciences reported audited standalone and consolidated results for the quarter and year ended March 31, 2025. Standalone revenue from operations collapsed to Rs. 294.28 lacs in FY25 from Rs. 1,441.32 lacs in FY24, a decline of roughly 80%. The company swung from a standalone profit of Rs. 31.74 lacs (FY24) to a loss of Rs. 96.74 lacs in FY25, with the consolidated loss coming in at Rs. 99.81 lacs versus a profit of Rs. 54.73 lacs last year. Operating cash flow turned sharply negative at Rs. (246.88) lacs standalone and Rs. (249.90) lacs consolidated, versus positive inflows of Rs. 179.52 lacs and Rs. 204.35 lacs in FY24. Other equity eroded from Rs. 71.53 lacs to just Rs. 2.04 lacs, while current borrowings more than doubled to Rs. 531.73 lacs. The Board also appointed a new Internal Auditor, Secretarial Auditor, an Independent Director, and reconstituted its committees.
The steep revenue fall, swing to losses, and negative operating cash flow point to serious business deterioration and financial stress for shareholders, likely weighing negatively on the stock. Rising borrowings against eroding equity also raise solvency concerns.